



Basic Information :

Name : Amr Abdel Moneim Abdel Rahman Saad

Title : Lecturer

Head of the Egyptian Pharmacovigilance Center (EPVC) and acting General Administrator for the General administrate for Pharmaceutical Research at the Central Administration for Pharmaceutical Affairs (CAPA), and part-time clinical lecturer at some Egyptian faculties of pharmacy

Education :

Certificate	Major	University	Year
PhD	Epidemiology, School of Pharmacy and Pharmaceutical Scinces	The University of Manchester, The United Kingdom	2009
Masters	Clinical Pharmacy, School of Pharmacy and Pharmaceutical Sciences	The University of Helwan	2003
Bachelor	Faculty of Pharmacy	Ain Shams University	2000

Teaching Experience :

Name Of Organization	Position	From Date	To Date
International Journal of Clinical Pharmacy (IJCP)	Peer Reviewer	01/06/2012	30/04/2014
Arab League	Co-ordinator for the Arab League's subcommittee to reach a unified Arab Pharmacovigilance regulations	01/04/2012	30/04/2014
Ain Shams University	Lecturer of Clinical Pharmacy	01/07/2010	30/04/2014
Egyptian Clinical Pharmacy Fellowship	Founding member in the Egyptian Clinical Pharmacy Fellowship	01/04/2010	30/04/2014
Egyptian Pharmacovigilance Center	Head of the Egyptian Pharmacovigilance Center (EPVC)	01/10/2009	30/04/2014
Manchester University, United Kingdom	Member of the Center for Innovation in Practice (CIP) Group	01/01/2007	01/10/2009
Manchester University, United Kingdom	Ph.D. Student and Teaching Assistant	01/09/2005	01/10/2009
The University of Helwan, Egypt	MSc Student	01/09/2001	01/09/2003
National Organisation for Drug Control and Research (NODCAR), Egypt	Assistant and Research Fellow of Clinical Pharmacy	01/01/2001	01/09/2005

Paper :

15- January 2006: Risk-benefit of new biologicals in the treatment of chronic plaque psoriasis. (with Darren Ashcroft, Peter Noyce and CEM Griffiths), presented at the Scientific Writing Tutorial at Manchester University, UK. 16- June 2006: Risk-benefit of new biologicals in the treatment of different Immune-Mediated Inflammatory Diseases. (with Darren Ashcroft, and Peter Noyce), presented at the PhD first year workshop of the school of Pharmacy and Pharmaceutical Sciences at Manchester University, UK. 17 - August 2006: Risk-benefit of new biologicals in the treatment of different Immune-Mediated Inflammatory Diseases (IMID). (with Darren Ashcroft, and Peter Noyce), presented at the Drug Usage and Pharmacy Practice group at Manchester University, UK. 18- April 2008: Efficacy and safety of anti-TNF therapies in psoriatic arthritis. (with Darren Ashcroft, Peter Noyce, Kath Watson, Kimme Hyrich, Peter Noyce, and Deborah Symmons), presented at The Manchester Salford and Trafford Branch of ROYAL PHARMACEUTICAL SOCIETY OF GREAT BRITAIN 19- June 2008: Efficacy and safety of anti-TNF therapies in psoriatic arthritis (PsA). (with Darren Ashcroft, Peter Noyce, Kath Watson, Kimme Hyrich, Peter Noyce, and Deborah Symmons), presented at the PhD third year workshop of the school of Pharmacy and Pharmaceutical Sciences at Manchester University, UK. 20- December 2009: Introductory presentation of Pharmacovigilance to members of the Central Administration of Pharmaceutical Affairs (CAPA) (with Hadir Mamdouh, Bassant Hassan), presented at the board meeting of the Central Administration of Pharmaceutical Affairs (CAPA). 21- December 2009: Presentation of Pharmacovigilance to members of the Chamber of Pharmaceutical industries,

presented at the meeting between members of the ministry of health and members of the Pharmaceutical companies at the pharmaceutical chamber. 22- January 2010: Presentation of Pharmacovigilance to members Business Men Club of the Scientific Offices, presented at the meeting between members of the ministry of health and members of the Business Men Club of the Scientific Offices. 23- March 2010: Presentation of Pharmacovigilance guidelines to members of the Central Administration of Pharmaceutical Affairs (CAPA), presented at the board meeting of the Central Administration of Pharmaceutical Affairs (CAPA). 24- April - June 2010: Weekly presentation of Pharmacovigilance to Health Care Professional (HCPs) and hospital pharmacists, presented at Mahed Nasr Hospital training center. 25- May 2010: Presentation of %controlling of counterfeit medicine- A counterfeit medicine conference, presented at counterfeit medicine conference held in Cairo. 26- May 2010: Presentation of Pharmacovigilance to Broncology Conference, presented at Broncology Conference held in Alexandria. 27- June 2010: Presentation of introduction to Pharmacovigilance to the Steering Committee for ICIUM 2011 at Ain Shams University. 28- June 2010: Presentation of introduction to Pharmacovigilance to Roche conference in Cairo. 29- July 2010: Presentation of Pharmacovigilance to Allergy Conference, presented at Allergy Conference held in Alexandria. 30- August 2010: Presentation of Egyptian Pharmacovigilance regulations to Otsuka conference meeting held in Cairo. 31- October 2010: Presentation basis of Pharmacovigilance and the role of Health Care Practitioners (HCPs) to SEARCHING AND APPRAISING THE LITERATURE ON ANTIBIOTIC MEDICATION (SALAM) course, Faculty of Medicine, Ain Shams University, Egypt. 32- January 2011: workshop to Unify Arabic terms and definitions within Arabic Pharmacovigilance Centers. 33- February to June 2011: Ten successive Pharmacovigilance Conferences for Physicians and their role in ADR reporting, National Training Institute (NTI), Cairo, Egypt. 34- March 2011: Presentation basis of Pharmacovigilance and the role of hospital pharmacists in ADR reporting Alexandria, Egypt. 35- June & July 2011: twenty successive Pharmacovigilance training workshops for Hospital pharmacists to enhance pharmacovigilance culture, Ministry of Health Hospitals, Egypt. 36- July 2011: Presentation Pharmacovigilance to undergraduate pharmacy students from 5 different Egyptian Universities, Cairo University. 37- July 2011: Presentation Pharmacovigilance to undergraduate pharmacy students from 5 different Egyptian Universities, Assuit University. 38- July 2011: Presentation Pharmacovigilance to Health Care professionals, Zagazig governorate. 39- July 2011: Presentation Pharmacovigilance to Health Care professionals, Al-Fayoum governorate. 40- September 2011: Presentation of the differences in Pharmacovigilance regulations to the Arab Union of The Manufacturers of Pharmaceuticals and Medical Appliances (AUPAM). 41- Summer 2011: Presentation of Pharmacovigilance to the Egyptian Health Care Providers (HCPs) in the PharmaKampus Campaign. 42- December 2011: Presentation of Pharmacovigilance to Marketing Authorization Holders (MAHs) in Training held at the National training Institute (NTI). 43- January 2012: Presentation of Pharmacovigilance to national Marketing Authorization Holders (MAHs) in Training held at the Holdi-Pharma (NTI). 44- March 2012: Presentation of Pharmacovigilance to Clinical Pharmacy fellows during the Egyptian Clinical Pharmacy fellowship course 2012/2013. 45- April 2012: Presentation of Advanced Pharmacovigilance during the second wave training to Marketing Authorization Holders (MAHs) in Training held at the National training Institute (NTI). 46- April 2012: Presentation of Advanced Pharmacovigilance during the %pharmacy innovation conference- organized by the faculty of pharmacy at the conference Center, Cairo University. 47- May 2012: Presentation of Excellence in Pharmacovigilance during the second wave of the %BV & Quality- A campaign to Hospital pharmacist, at the National Training Institute NTI, Cairo. 48- May 2012: Presentation of Excellence in Pharmacovigilance during the second wave of the %BV & Quality- A campaign to Hospital pharmacist, Alexandria. 49- May 2012: Presentation of Excellence in Pharmacovigilance to Health Care Professionals working in the Police hospitals. 50- May 2012: Presentation of Excellence in Pharmacovigilance in the United Sates Pharmacopeia %USP- A conference for %Counteracting counterfeit medicines and Sub-standard copies- A Cairo, Egypt. 51- May/June 2012: Presentation of Excellence in Pharmacovigilance in the %East African/middle-East summit for hospital Pharmacist- A Dubai, Emirates. 52- June 2012: Presentation of %Pharmacovigilance in Clinical Trials- A principal and Co-investigators participating in RCTS conducted in Egypt, Alexandria. 53- June/July 2012: Presentation of %Pharmacovigilance- A physicians in the Medical Campus campaign for university hospital doctors, different University Hospitals, Egypt. 54- July 2012: Presentation of %Detailed Description of Pharmacovigilance Systems (DDPS), Periodic Safety Update Reports (PSURs) & Individual Case Safety Reports (ICSRs)- A Pharma-companies and Marketing Authorization Holders (MAHs) licensed in Egypt at the National Training Institute (NTI), Cairo, Egypt. 55- August 2012: Presentation of %Pharmacovigilance from the HCPs prospective- A Pharmacists working in Alexandria, Alexandria Branch of the Pharmacy Syndicate, Alexandria. 56- September/October 2012: Training HCPs on %Pharmacovigilance- A in 13 different rounds at 13 different Health Care Facilities, Cairo, Egypt. 57- October 2012: Training HCPs on %Pharmacovigilance- A in Police and Military Medical Academies, Cairo, Egypt. 58- October 2012: Training HCPs on %Pharmacovigilance- A in El-Salam International Hospital, Cairo, Egypt. 59- October-December 2012: Training 600 HCPs on %Pharmacovigilance- A in a WHO programme for Egyptian HCPs, Cairo, Egypt. 60- October 2012 - June 2013: Training 900 HCPs on %Pharmacovigilance- A in a Egyptian Ministry of Health, Cairo, Egypt. 61- November 2012: Training Marketing Authorization Holders (MAHs) on PSURs regulations and guidelines, Novatel, Cairo, Egypt. 62- November 2012: Training Biosimilars producing industries on Risk Management Planes for Biosimilars, NTI, Cairo, Egypt. 63- November/December 2012: eight training waves for Medical Doctors on Pharmacovigilance, Medical Campus campaign, Cairo, Egypt. 64- December 2012: Training Hikma Company on the Egyptian Regulation for Pharmacovigilance, Amman, Jordon. 65- December 2012: Training Holdi-Pharma on Individual Case Reports (ICSRs) regulations and guidelines, Holdi-Pharma plant. 66- January 2013: Presenting the Role of Pharmacist as a corner stone in Pharmacovigilance activities, Egyptian Pharmaceutical Association, Convention Center, Cairo University, Egypt. 67- January 2013: Presenting the Role of Pharmacovigilance in Hepatitis C viruses (HCV) medication, HCV Academy, Palestine Hotel, Alexandria, Egypt. 68- February 2013: Training HCPs in Dubai, UAE on Pharmacovigilance during the Second Hospital Summit, Dubai, UAE. 69- February 2013: Training Pharma industries on Regulations and Contents of Risk Management Planes (RMPs). 70- February 2013: Training Pharma industries on Regulations and Contents of Risk Management Planes (RMPs). 71- March 2013: Training HCPS at: Military Medical Acedamy, Cairo University Hospitals, Nasr institute, Mahla Cardiac Center on Adverse Drug Reaction ADR reporting. 72- March 2013: Training HCPS at: Egyptian Clinical Pharmacy Fellowship and Police Medical Academy on Adverse Drug Reaction ADR reporting. 73- April 2013: Presenting the Role of Marketing Authorization Holders (MAHs) in Pharmacovigilance activities, The conference of "future of Pharma industries", Cairo Convention Center, Egypt. 74- April 2013: Presenting the Good Pharmacovigilance Practices, The Third conference of "Arab Pharma industries", Beirut, Lebanon. 75- April 2013: Presenting the Pharmacovigilance HCPs perspective, The MSA conference,

MSA University, Egypt. 76- May 2013: Presenting the Role of DIC in Pharmacovigilance, Arab Constructors` Main Hospital; Cairo, Egypt. 77- May 2013: Presenting Risk Management Plans (RMPs) in Biological Products, Launching Onco-line for Oncology Physicians; Ghardaga, Egypt. 78- May 2013: Presenting Integrating Clinical Pharmacy with Pharmacovigilance, Cairo University Medical Hospitals; Cairo, Egypt. 79- May 2013: Presenting Risk Management Plans (RMPs) & Egyptian regulations for Marketing Authorization Holders (MAHs), 3rd RMP and PV conference, Dubai, UAE. 80- May - June 2013: Waves of 21 Workshops (20 attendees per each) about Excellence in Pharmacovigilance for different Hospital Pharmacists across 21 different Egyptian Health Governorate, Ministry of Health, Egypt. 81- June 2013: Integrating DIC with PV activities for hospital Pharmacists, Alex, Egypt. 82- July 2013: 4-days workshop for training Qualified Persons for Pharmacovigilance (QPPVs) across 42 different Alexandrian Hospitals, as well as, Satellite Center team members, Alex, Egypt. 83- August 2013: 1-day workshop to train Hospital Pharmacist working at health insurance hospitals on Pharmacovigilance, Nasr City Health Insurance Hospital, Cairo, Egypt. 84- October 2013: 3-days workshop for training new recruited pharmacists in the different departments of the Egyptian Pharmaceutical Vigilance Center (EPVC), Horus Hall, Central Administration for Pharmaceutical Affairs (CAPA). 85- November 2013: 3-days workshop for training Hospital Pharmacist working in different Libyan Hospitals on Pharmacovigilance, Corinthia Hotel, Tripoli, Libya.

Gihan H. Elsisy MSc1, Randa Eldessouki MSc, MD2, Mahmoud D. Elmahdawy PharmD1, Amr Saad MSc, PhD3, Samah Ragab MPA4, Mohy Mazar MSc, PhD5 ,Amr M. Elshalaqany MD, MBA6, Sherif Abaza MBA7 (2012); Recommendations for Egyptian Pharmacoeconomic Evaluation Guidelines

El-Said, SawsanAboul-fotouh; Saad, Amr; Hassan, Ahmed Noureldin; Hamza, May; Abdel-tawab, Ahmed Mohyeldin. Implementing an Egyptian Pharmacovigilance system: University and Public Hospitals` experience. International Conferences on Improving Use of Medicines (ICIUM2011).

Saad, A.A.; Ashcroft, D.M.; Watson, K.D.; Symmons, D.P.; Noyce, P.R.; Hyrich, K.L. Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-TNF therapies: data from the BSR Biologics Register (BSRBR). Pharmacoeconomics and Drug Safety 2009; S258

Saad, A.A.; Ashcroft, D.M.; Watson, K.D.; Hyrich, K.L.; Noyce, P.R.; Symmons, D.P. Efficacy and safety of anti-TNF agents in psoriatic arthritis: Results from the BSR biologics register. Rheumatology 2008; 47(ii): 80-81

Saad, A.A.; Ashcroft, D.M.; Watson, K.D.; Hyrich, K.L.; Noyce, P.R.; Symmons, D.P. Drug persistence on anti-TNF-? agents in psoriatic arthritis. Pharmacoeconomics and Drug Safety 2008; 17 (1): S192

Saad, A.A.; Noyce, P.R.; Griffiths, C.E.M.; Ashcroft, D.M. Using Bayesian methods in evidence synthesis: Examining the risk-benefit ratio of TNF inhibitors with direct and indirect comparisons. International Journal Of Pharmacy Practice 2007; (Suppl1):A25

Saad, A.A.; Noyce, P.R.; Griffiths, C.E.M.; Ashcroft, D.M. Using Bayesian methods in evidence synthesis: Examining the risk-benefit ratio of TNF inhibitors with direct and indirect comparisons. International Journal Of Pharmacy Practice 2007; (Suppl1):A25

Saad, A.A.; Ashcroft, D.M.; Griffiths, C.E.M.; Noyce, P.R. Risk-benefit of new biologicals in the treatment of chronic plaque psoriasis. International Journal Of Pharmacy Practice 2006; (Suppl 2): B60

Awards :

Award	Donor	Date
3- A scholarship to attend the 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management in Copenhagen, Denmark.	Copenhagen, Denmark.	01/01/2008
2- The University of Manchester Conference Travel	Manchester, UK	01/01/2006
1- A full scholarship (covers: tuition fees, bench fees and living expenses) for studying PhD in Pharmacy Practice at Manchester Universities from the Egyptian Government.	Travel to UK	01/01/2005
A certificate of the Ideal University Student - all over twenty eight different national Egyptian universities in a competition held within the Preparing the Future Leaders programme	Cairo, Egypt	01/01/2000